Dr. Persky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Tucson, AZ 85719Phone+1 520-694-2873Fax+1 520-694-0848
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
Albert Einstein College of MedicineClass of 2000
Harvard UniversityAB, Biochemical Sciences, Magna Cum Laude, 1992 - 1996
Certifications & Licensure
AZ State Medical License 2002 - 2025
CT State Medical License 2012 - 2014
NY State Medical License 2003 - 2006
MN State Medical License 2001 - 2003
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma Start of enrollment: 2010 Nov 15
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
- S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma Start of enrollment: 1997 Sep 15
- Join now to see all
Publications & Presentations
PubMed
- 134 citationsInteractions of Elongation Factor 1α with F-Actin and β-Actin mRNA: Implications for Anchoring mRNA in Cell ProtrusionsGang Liu, Wayne M. Grant, Daniel O. Persky, Vaughan Latham, Robert H. Singer
Molecular Biology of the Cell. 2002-02-01 - 104 citationsOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Kristie A. Blum, Christina Howlett
Journal of Clinical Oncology. 2017-05-05 - 84 citationsThe dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in...Luis F. Porrata, Morie A. Gertz, Susan Geyer, Mark R. Litzow, Dennis A. Gastineau
Leukemia. 2004-06-01
Journal Articles
- Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyShahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia
- Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell LymphomaDaniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research
Abstracts/Posters
- Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyNovember 2018
Press Mentions
Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia ManagementDecember 22nd, 2021- Many Non-Hodgkin's Lymphoma Patients Can Skip Radiation, Collaborative Study FindsOctober 6th, 2020
Study: Most with Early DLBCL Can Skip RTDecember 9th, 2019
Grant Support
- 2014 Cancer Clinical Investigator Team Leadership AwardNCIPresent
Committees
- Member, SWOG Lymphoma Working Committee
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
